Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05397171 · ClinicalTrials.gov registry record · Phase 1
A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT05397171 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 17 participants.
The verdict
NCT05397171, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.
Interventions
- DRUG AZD8853
- DRUG Zirconium-89 crefmirlimab berdoxam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2022-06-07 |
| Est. Completion | 2023-06-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05397171
The ClinicalTrials.gov registry entry for NCT05397171 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AZD8853 is the first listed.
NCT05397171 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05397171 about?
NCT05397171 is a clinical study titled "A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid Tumours". A Phase I/IIa First-in-human, Open-label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD8853 in Participants with Selected Advanced/Metastatic Solid Tumours.
What is the current status of trial NCT05397171?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2022-06-07. Estimated completion is 2023-06-06.
What interventions are being tested in trial NCT05397171?
The interventions under investigation include: AZD8853 (DRUG), Zirconium-89 crefmirlimab berdoxam (DRUG).
Who is sponsoring clinical trial NCT05397171?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.